Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALS-L1023 in Abdominal Obesity of Metabolic Syndrome
NCT01872182Phase 3Terminated
- Sponsor
- Hanmi Pharmaceutical
- Start
- May 2013
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ALS-L1023 in abdominal obesity, metabolic syndrome, sponsored by Hanmi Pharmaceutical. Started May 2013; status: terminated.
02
Drugs
ALS-L1023
03
Conditions
abdominal obesitymetabolic syndrome
Beyond the preview
Go deeper on NCT01872182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01872182.